Microcap Ledger Traws Pharma, Inc. $TRAW
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Newtown, PA
- Fiscal year end
- December 31
- Shares outstanding
- 15,368,277 [10-Q 2026-08-14]
What the company doesAI summary of filing
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for respiratory viral diseases and oncology. The company's primary focus is on antiviral agents, including tivoxavir marboxil for influenza and bird flu treatment, ratutrelvir for COVID-19, and legacy oncology programs including narazaciclib and rigosertib. The company generates revenue through milestone payments and royalties from licensing agreements with partners in various regions and does not yet have approved products. Following a merger in April 2024 with Trawsfynydd Therapeutics, the company transitioned from cancer-focused development to prioritizing respiratory viral disease programs. [10-K 2026-04-15]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$10.16M | −$10.08M | $5.02M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $2.79M | $9.17M | −$18.18M | $3.82M | [10-K 2026-04-15] |
| FY ended Dec 2024 | $226.0K | −$166.52M | −$29.79M | $21.34M | [10-K 2026-04-15] |
- Quarterly cash burn
- −$5.04M
- Cash runway Estimate
- ~3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-04-28 | 5,334,015 | [10-K/A 2025-04-30] |
| 2025-05-13 | 5,564,315 | [10-Q 2025-05-15] |
| 2025-08-12 | 7,063,829 | [10-Q 2025-08-14] |
| 2025-11-10 | 7,990,867 | [10-Q 2025-11-13] |
| 2026-04-13 | 10,157,257 | [10-K 2026-04-15] |
| 2026-04-24 | 15,150,669 | [10-K/A 2026-04-30] |
| 2026-05-12 | 15,150,669 | [10-Q 2026-05-15] |
| 2026-08-12 | 15,368,277 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-07-01; declared effective 2026-07-09 [S-3 2026-07-01]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-31. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-07-31 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-31] |
| 2024-11-22 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-11-22] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-08 | PRE 14A | Proxy statement |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-14 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-31 | 8-K | Listing notice or transfer |
| 2026-07-10 | 8-K | Other events |
| 2026-07-10 | 424B5 | Prospectus or prospectus supplement |
| 2026-07-09 | 8-K | Director or officer change; Shareholder vote results |
| 2026-07-01 | S-3 | Registration statement |
Alerts for $TRAW
Email me when Traws Pharma, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.